Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Trastuzumab-induced cardiotoxicity may induce reversible damage that is usually transitory and improves with trastuzumab withdrawal. In clinical trials with trastuzumab in the adjuvant setting ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

[166] The HER2 mAb pertuzumab represents a new class of drugs called dimerization inhibitors; these have the potential to block signaling by ... drugs with other key pathways, will lead to the ...

and the HER2 signaling pathways in breast cancer. The major objectives of this research group are to explore the key oncogenic/signaling networks, develop biomarkers to design tailored targeted ...

which indicates that lapatinib exerts its main effects via the HER2 pathway. Around 1.3 million women are diagnosed with breast cancer annually worldwide, which represents 23% of all cancers in women.

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

and the higher expressions of the proto-oncogenes HER2 and c-Myc. 2 Hsp90 inhibitors may selectively inhibit the signal-transduction pathways amplified in cancer cells. The recent progress in ...

One of them is relying on the HER2 protein, whose overexpression helps it multiply faster. Up to 4% of all tumors have high ...

We have shown that tumors with HER2 amplification or PI3K mutation are selectively dependent for growth on the PI3K pathway and are sensitive to specific inhibitors of PI3K or AKT. Inhibition of PI3K ...